Joseph Hernandez1, Steven G Chopski2, Sam Lee3, William B Moskowitz3, Amy L Throckmorton2. 1. Department of Biomedical Engineering, School of Engineering, Virginia Commonwealth University, Richmond, VA, USA. 2. BioCirc Research Laboratory, School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, USA. 3. Division of Pediatric Cardiology, The Children's Hospital of Richmond, and School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.
Abstract
BACKGROUND: Limited therapeutic options are available for Fontan patients with dysfunctional or failing single ventricle physiology. This study describes the evaluation of an alternative, non-invasive, at-home therapeutic compression treatment for Fontan patients. Our hypothesis is that routinely administered, externally applied compression treatments to the lower extremities will augment systemic venous return, improve ventricular preload, and thus enhance cardiac output in Fontan patients. METHODS: To initially evaluate this hypothesis, we employed the NormaTec pneumatic compression device (PCD) in a pilot clinical study (n=2). This device is composed of inflatable trouser compartments that facilitate circumferentially and uniformly applied pressure to a patient's lower extremities. Following an initial health screening, test subjects were pre-evaluated with a modified-Bruce treadmill exercise stress test, and baseline data on cardiorespiratory health was collected. After training, test subjects conducted 6 days of external compression therapy at-home. Subjects were then re-evaluated with a final treadmill stress test and data acquisition of new cardiorespiratory parameters. RESULTS: Both subjects demonstrated improvement in exercise duration time, peak oxygen volume, and ventilator threshold, as compared to the baseline evaluation. CONCLUSIONS: These findings are promising and provide the foundation for future studies that will focus on increasing study participation (sample size) to better assess the clinical benefit of compression therapy for Fontan patients.
BACKGROUND: Limited therapeutic options are available for Fontan patients with dysfunctional or failing single ventricle physiology. This study describes the evaluation of an alternative, non-invasive, at-home therapeutic compression treatment for Fontan patients. Our hypothesis is that routinely administered, externally applied compression treatments to the lower extremities will augment systemic venous return, improve ventricular preload, and thus enhance cardiac output in Fontan patients. METHODS: To initially evaluate this hypothesis, we employed the NormaTec pneumatic compression device (PCD) in a pilot clinical study (n=2). This device is composed of inflatable trouser compartments that facilitate circumferentially and uniformly applied pressure to a patient's lower extremities. Following an initial health screening, test subjects were pre-evaluated with a modified-Bruce treadmill exercise stress test, and baseline data on cardiorespiratory health was collected. After training, test subjects conducted 6 days of external compression therapy at-home. Subjects were then re-evaluated with a final treadmill stress test and data acquisition of new cardiorespiratory parameters. RESULTS: Both subjects demonstrated improvement in exercise duration time, peak oxygen volume, and ventilator threshold, as compared to the baseline evaluation. CONCLUSIONS: These findings are promising and provide the foundation for future studies that will focus on increasing study participation (sample size) to better assess the clinical benefit of compression therapy for Fontan patients.
Authors: Sjoerd S M Bossers; Willem A Helbing; Nienke Duppen; Irene M Kuipers; Michiel Schokking; Mark G Hazekamp; Ad J J C Bogers; Arend D J Ten Harkel; Tim Takken Journal: J Thorac Cardiovasc Surg Date: 2014-01-15 Impact factor: 5.209
Authors: K Anitha Jayakumar; Linda J Addonizio; Maryanne R Kichuk-Chrisant; Mark E Galantowicz; Jacqueline M Lamour; Jan M Quaegebeur; Daphne T Hsu Journal: J Am Coll Cardiol Date: 2004-11-16 Impact factor: 24.094